Serum mesothelin for diagnosing malignant pleural mesothelioma: An individual patient data meta-analysis

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1541-1549

  Hollevoet, Kevin ^a,n   Reitsma, Johannes B ^c   Creaney, Jenette ^e   Grigoriu, Bogdan D ^f   Robinson, Bruce W ^e   Scherpereel, Arnaud ^g   Cristaudo, Alfonso ^h   Pass, Harvey I ^o   Nackaerts, Kristiaan ^b   Rodríguez Portal, José A ^k   Schneider, Joachim ^l   Muley, Thomas ^m   Di Serio, Francesca ⁱ   Baas, Paul ^d   Tomasetti, Marco ^j   Rai, Alex J ^p   Van Meerbeeck, Jan P ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY OF PISA   (Italy)

ⁱ POLICLINICO   (Italy)

^j UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l JUSTUS LIEBIG UNIVERSITY   (Germany)

^m UNIVERSITY OF HEIDELBERG   (Germany)

ⁿ NATIONAL CANCER INSTITUTE   (United States)

^o NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^p NewYork Presbyterian Hospital   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MESOTHELIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TUMOR MARKER;

AREA UNDER THE CURVE; CANCER PATIENT; CANCER STAGING; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; META ANALYSIS; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; FEMALE; MALE; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PLEURA TUMOR; PREDICTIVE VALUE; PROGNOSIS;

AGED; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GPI-LINKED PROTEINS; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84862991636     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.6671     Document Type: Review

References (49)

1. Robinson BW, Musk AW, Lake RA: Malignant mesothelioma. Lancet 366:397-408, 2005
2. Scherpereel A, Astoul P, Baas P, et al: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35:479-495, 2009
3. LaDou J, Castleman B, Frank A, et al: The case for a global ban on asbestos. Environ Health Perspect 118:897-901, 2010
4. Tsao AS, Wistuba I, Roth JA, et al: Malignant pleural mesothelioma. J Clin Oncol 27:2081-2090, 2009
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644, 2003
6. van Meerbeeck JP, Gaafar R, Manegold C, et al: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881-6889, 2005
7. Weder W, Opitz I, Stahel R: Multimodality strategies in malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 21:172-176, 2009
8. Whitaker D: The cytology of malignant mesothelioma. Cytopathology 11:139-151, 2000
9. Hassan R, Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer 44:46-53, 2008
10. Scholler N, Fu N, Yang Y, et al: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 96:11531-11536, 1999
11. Hellstrom I, Raycraft J, Kanan S, et al: Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 15:1014-1020, 2006
12. Robinson BW, Creaney J, Lake R, et al: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612-1616, 2003
13. Li Z, Verch T, Allard JW: MESOMARK in vitro diagnostic test for mesothelioma. Expert Opin Med Diagn 1:137-142, 2007
14. Whiting P, Rutjes AW, Reitsma JB, et al: The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25, 2003
15. Beyer HL, Geschwindt RD, Glover CL, et al: MESOMARK: A potential test for malignant pleural mesothelioma. Clin Chem 53:666-672, 2007
16. Hollevoet K, Nackaerts K, Thimpont J, et al: Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 181:620-625, 2010
17. Reitsma JB, Glas AS, Rutjes AW, et al: Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58:982-990, 2005
18. Riley RD, Higgins JP, Deeks JJ: Interpretation of random effects meta-analyses. BMJ 342:964-967, 2011
19. Janes H, Pepe MS: Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: An old concept in a new setting. Am J Epidemiol 168:89-97, 2008
20. Mandrekar JN: Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 5:1315-1316, 2010
21. Grimes DA, Schulz KF: Refining clinical diagnosis with likelihood ratios. Lancet 365:1500-1505, 2005
22. Hassan R, Remaley AT, Sampson ML, et al: Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12:447-453, 2006
23. Iwahori K, Osaki T, Serada S, et al: Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin. Lung Cancer 62:45-54, 2008
24. Amati M, Tomasetti M, Scartozzi M, et al: Profiling tumor-associated markers for early detection of malignant mesothelioma: An epidemiologic study. Cancer Epidemiol Biomarkers Prev 17:163-170, 2008
25. Creaney J, Christansen H, Lake R, et al: Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 1:172-174, 2006
26. Scherpereel A, Grigoriu B, Conti M, et al: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173:1155-1160, 2006
27. Creaney J, van Bruggen I, Hof M, et al: Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 132:1239-1246, 2007
28. Grigoriu BD, Scherpereel A, Devos P, et al: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13:2928-2935, 2007
29. Creaney J, Yeoman D, Naumoff LK, et al: Soluble mesothelin in effusions: A useful tool for the diagnosis of malignant mesothelioma. Thorax 62:569-576, 2007
30. Di Serio F, Fontana A, Loizzi M, et al: Mesothelin family proteins and diagnosis of mesothelioma: Analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 45:634-638, 2007
31. Cristaudo A, Foddis R, Vivaldi A, et al: Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 13:5076-5081, 2007
32. van den Heuvel MM, Korse CM, Bonfrer JM, et al: Non-invasive diagnosis of pleural malignancies: The role of tumour markers. Lung Cancer 59:350-354, 2008
33. Creaney J, Yeoman D, Demelker Y, et al: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 3:851-857, 2008
34. Pass HI, Wali A, Tang N, et al: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85:265-272, 2008
35. Schneider J, Hoffmann H, Dienemann H, et al: Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 3:1317-1324, 2008
36. Grigoriu B, Chahine B, Zerimech F, et al: Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem 42:1046-1050, 2009
37. Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al: Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: Relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 18:646-650, 2009
38. Rai AJ, Flores RM, Mathew A, et al: Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: Analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med 48:271-278, 2010
39. Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14:1-12, 1996
40. American Joint Committee on Cancer: Handbook for Staging of Cancer (ed 4). Philadelphia, PA, J.B. Lippincott Co, 1993, pp 137-138
41. Luo L, Shi HZ, Liang QL, et al: Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: A meta-analysis. Respir Med 104:149-156, 2009
42. van der Bij S, Schaake E, Koffijberg H, et al: Markers for the non-invasive diagnosis of mesothelioma: A systematic review. Br J Cancer 104:1325-1333, 2011
43. Hollevoet K, Nackaerts K, Thas O, et al: The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest [epub ahead of print on July 7, 2011]
44. Hollevoet K, Van Cleemput J, Thimpont J, et al: Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: A prospective longitudinal cohort study. J Thorac Oncol 6:889-895, 2011
45. Creaney J, Olsen NJ, Brims F, et al: Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 19:2238-2246, 2010
46. Grigoriu BD, Chahine B, Vachani A, et al: Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 179:950-954, 2009
47. Wheatley-Price P, Yang B, Patsios D, et al: Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 28:3316-3322, 2010
48. Creaney J, Francis RJ, Dick IM, et al: Serum soluble mesothelin concentrations in malignant pleural mesothelioma: Relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 17:1181-1189, 2011
49. Hollevoet K, Nackaerts K, Gosselin R, et al: Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol 6:1930-1937, 2011